UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
 
Date of Report (date of earliest event reported): January 9, 2024
 
Elicio Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
001-39990
11-3430072
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(IRS Employer Identification No.)

451 D Street, 5th Floor
Boston, Massachusetts 02210
(Address of principal executive offices, including zip code )
 
(857) 209-0050
Registrant’s telephone number, including area code
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
(Title of each class)
(Trading Symbol)
(Name of exchange on which registered)
Common Stock, $0.01 par value per share
ELTX
 The Nasdaq Global Select Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☒
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Item 8.01
Other Events.

On January 9, 2024, Elicio Therapeutics, Inc. (the “Company”) issued a press release announcing the publication of updated preliminary data from the Company’s ongoing Phase 1 (AMPLIFY-201) solid tumor study of its lead asset, ELI-002, in Nature Medicine. A copy of the press release is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference. Attached as Exhibit 99.2 and incorporated herein by reference is an updated version of the Company’s corporate presentation, which was uploaded to the Company’s website on January 9, 2024.

Item 9.01.
Financial Statements and Exhibits.

(d)
Exhibits.

Exhibit
Number
   
Exhibit
Description
 
Press Release of Elicio Therapeutics, Inc., dated January 9, 2024
 
Corporate presentation dated January 9, 2024
104
  
Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Elicio Therapeutics, Inc.




By:
/s/ ROBERT CONNELLY


Robert Connelly
President and Chief Executive Officer
(Principal Executive Officer)
Date:  January 9, 2024